MedPath

Treatment of Actinic keratosis: topical ingenol mebutate versus 5%5-fluorouracil versus 5% imiquimod versus photodynamic therapy.

Conditions
Actinic keratosis
Registration Number
NL-OMON22756
Lead Sponsor
K. Mosterd, dermatologistMaastricht University Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
624
Inclusion Criteria

Patients older than 18 years

- Female in child bearing potential should be using contraceptive measures, during and till 3 months post-treatment

Exclusion Criteria

- Received any kind of treatment for AK in the past 3 months

- (N)MSC in target area

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome measure: treatment success (i.e. the proportion of patients with >75% lesion reduction in the number of AK lesions counted at baseline in the treatment area) 12 months post treatment.
Secondary Outcome Measures
NameTimeMethod
- Partial response (proportion of participants at 12 months post treatment with 50-75% reduction in number of AK lesions)<br /><br>- Treatment failure (proportion of participants at 12 months post treatment with <50% reduction in number of AK lesions)<br /><br>- Complete lesion clearance (proportion of lesions with 100% clearance in all treated patients per study arm)<br /><br>- Partial lesion clearance (proportion of lesions with >75% clearance in all treated patients per study arm)<br /><br>- Decrease in number AK from baseline per patient<br /><br>- Number of SCC¡¯s developing in the treatment area<br /><br>- Healthcare/treatment costs<br /><br>- Side effects<br /><br>- Patient satisfaction<br /><br>- Cosmetic outcome <br /><br>- Treatment compliance
© Copyright 2025. All Rights Reserved by MedPath